Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06177912 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 882
- Enrollment target
NCT06177912 is a Phase 3 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 882 participants.
The verdict
NCT06177912, a Phase 3 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 882 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of V116 compared to PPSV23 in children and teenagers 2 through 17 years of age, who had completed routine pneumococcal vaccine as infants/toddlers. Researchers want to learn if V116 is as good as, or is better than the PPSV23 vaccine in terms of the antibody immune response. V116 and PPSV23 will be studied in children and teenagers who have a higher risk of getting pneumococcal disease (PD).
Interventions
- BIOLOGICAL V116
- BIOLOGICAL PPSV23
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 882 participants |
| Start Date | 2024-01-18 |
| Est. Completion | 2025-02-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06177912
The ClinicalTrials.gov registry entry for NCT06177912 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 882 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which V116 is the first listed.
NCT06177912 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06177912 about?
NCT06177912 is a clinical study titled "A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)". The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of V116 compared to PPSV23 in children and teenagers 2 through 17 years of age, who had completed routine pneumococcal vaccine as infants/toddlers. Researchers want to learn if V116 is as good as, or is better than...
What is the current status of trial NCT06177912?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 882 participants. The study started on 2024-01-18. Estimated completion is 2025-02-26.
What interventions are being tested in trial NCT06177912?
The interventions under investigation include: V116 (BIOLOGICAL), PPSV23 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06177912?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.